How much is the gestational trophoblastic disease market worth, and how is it expected to expand?
The gestational trophoblastic disease market size has grown strongly in recent years. It will grow from $2.06 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to public health initiatives, improved understanding of disease pathology, medical research and clinical trials, development of targeted therapies, shift in treatment protocols.
The gestational trophoblastic disease market size is expected to see steady growth in the next few years. It will grow to $2.64 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to healthcare infrastructure development, enhanced telemedicine and remote care, patient-centric care approaches, regulatory approvals for novel treatments, genomic and molecular studies. Major trends in the forecast period include shift towards personalized medicine, advancements in molecular diagnostics, focus on immunotherapies and targeted therapies, integration of digital health technologies, rising awareness and education programs.
Get Your Free Sample of The Global Gestational Trophoblastic Disease Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13271&type=smp
What are the top drivers to the rising demand in the gestational trophoblastic disease market?
The growth in abnormal pregnancies is expected to propel the growth of the gestational trophoblastic disease market going forward. Abnormal pregnancies refer to pregnancies that deviate from the typical or expected course and may pose risks to the health of the mother, the fetus, or both. In abnormal pregnancies, such as molar pregnancies, the trophoblast develops into a tumor instead of a fetus, resulting in gestational trophoblastic disease. For instance, in May 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, in 2022, there were 251,377 abortions for women residing in England and Wales—the highest number recorded since the Abortion Act was introduced, marking a 17% increase from the previous year. Therefore, the growth in abnormal pregnancies is driving the gestational trophoblastic disease market.
How is the gestational trophoblastic disease market segmented?
The gestational trophoblastic disease market covered in this report is segmented –
1) By Type: Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Other Types
2) By Treatment: Surgery, Chemotherapy, Suction Dilation And Curettage (D&C), Radiation Therapy
3) By End User: Hospital And Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Hydatidiform Mole: Complete Hydatidiform Mole, Partial Hydatidiform Mole
2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma, Metastatic Choriocarcinoma
3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation, PSTT With Abnormal Placentation
4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis, Epithelioid Trophoblastic Tumor With Metastasis
5) By Other Types: Trophoblastic Tumor Of Unknown Origin, Non-Gestational Trophoblastic Neoplasia
Order your report now for swift delivery
Who are the top competitors in the gestational trophoblastic disease market?
Major companies operating in the gestational trophoblastic disease market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Mylan N.V, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Perrigo Company PLC, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., Wockhardt Ltd., Natco Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Arog Pharmaceuticals Inc., Advenchen Laboratories LLC., Mendus AB, AB Science S.A.
What significant trends should we anticipate in the gestational trophoblastic disease market over the forecast period?
Major companies operating in the gestational trophoblastic disease market are introducing guidelines to provide reliable services to customers. The launch of the updated guideline ensures a comprehensive review of current diagnostic and management strategies for patients with GTD. It provides doctors and nurses with the necessary information to achieve excellence in the care of these patients. For instance, in May 2022, the Health Service Executive (HSE) National Cancer Control Programme (NCCP), an Ireland-based provider of public health and social care services, launched the updated gestational trophoblastic disease (GTD) guideline at the European organization for the treatment of trophoblastic disease. This guideline integrates the best current research evidence with clinical expertise and patient values. It aims to reduce variation in practice and improve the quality of care delivered to patients.
Innovative Reproductive Tissue Preservation Solutions In The Gestational Trophoblastic Disease Market
Major companies operating in the gestational trophoblastic disease market are developing innovative treatments, such as reproductive tissue preservation solutions, to provide reliable services to customers. A reproductive tissue preservation solution preserves the viability of reproductive tissue, such as sperm, eggs, embryos, and ovarian tissue, typically composed of a mixture of cryoprotectants that help to protect cells from the damage caused by freezing. For instance, in June 2022, Inception Fertility LLC, a US-based fertility care provider, launched HavenCryo, a long-term reproductive tissue and cryopreservation storage solution. HavenCryo offers a unique experience for fertility providers and patients by storing reproductive tissue, including oocytes (eggs), sperm, and embryos, for an indefinite time. This gives patients more family-building flexibility, peace of mind, and control over their reproductive choices. HavenCryo can store eggs or embryos for women diagnosed with gestational trophoblastic disease (GTD) and need to undergo treatment that could damage their fertility.
Which regional trends are influencing the gestational trophoblastic disease market, and which area dominates the industry?
Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Gestational Trophoblastic Disease Market Report 2025 Offer?
The gestational trophoblastic disease market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Gestational trophoblastic disease (GTD) refers to a group of rare and abnormal conditions that develop from the abnormal growth of trophoblastic cells that develop a tumor inside the uterus after conception. The treatment of GTD involves uterine evacuation and monitoring human chorionic gonadotropin (hCG) levels.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13271
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
